Kairos Pharma (NYSE: KAPA) sets KOL event on ENV105 data

Rhea-AI Filing Summary

Kairos Pharma, Ltd. reported that it will host a premier key opinion leader (KOL) event on September 18, 2025 at 5 p.m. ET / 2 p.m. PT. The event will focus on diverse perspectives regarding interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients. The company furnished a related press release as Exhibit 99.1, noting that this information is being provided under an “Other Events” item and is treated as furnished rather than filed under the securities laws.

false 0001962011 0001962011 2025-09-11 2025-09-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2025

Kairos Pharma, Ltd.

(Exact name of registrant as specified in its charter)

Delaware		001-42275		46-2993314
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2355 Westwood Blvd., #139

Los Angeles CA 90064

(Address of principal executive offices) (Zip Code)

(310) 948-2356

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol (s)		Name of each exchange on which registered
Common Stock, par value $0.001, per share		KAPA		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 11, 2025, Kairos Pharma, Ltd., a Delaware corporation (the “Company”), issued a press release announcing that it will host a premier KOL event on Thursday, September 18, 2025 at 5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the Company’s interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients.

A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Item 8.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information of the information contained in this Item 8.01, including Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated September 11, 2025
104		Cover Page Interactive Data File (embedded within Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 11, 2025	KAIROS PHARMA, LTD.
	By:	/s/ John S. Yu
		John S. Yu
		Chief Executive Officer

FAQ

What did Kairos Pharma (KAPA) disclose in this 8-K filing?

Kairos Pharma disclosed that it will host a premier KOL event on September 18, 2025 to discuss perspectives on interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in advanced prostate cancer.

When is Kairos Pharma's ENV105 KOL event scheduled to take place?

The KOL event is scheduled for Thursday, September 18, 2025 at 5 p.m. ET / 2 p.m. PT.

What is the focus of the ENV105 Phase 2 trial discussed by Kairos Pharma?

The Phase 2 trial of ENV105 that will be discussed at the KOL event focuses on treating advanced prostate cancer patients and will cover interim efficacy results.

How is the information about the Kairos Pharma KOL event treated under securities laws?

The company states that the information in Item 8.01, including Exhibit 99.1, is furnished and not deemed filed under Section 18 of the Exchange Act and is not automatically incorporated by reference into other Securities Act or Exchange Act filings.

What exhibit did Kairos Pharma attach related to the KOL event?

Kairos Pharma attached Exhibit 99.1, described as a press release dated September 11, 2025, and also listed Exhibit 104 as the cover page interactive data file.

Who signed the Kairos Pharma 8-K related to the ENV105 KOL event?

The 8-K was signed on behalf of Kairos Pharma, Ltd. by John S. Yu, who is identified as the company’s Chief Executive Officer.